Fasting Insulin and HOMA-IR: The Biomarkers That Catch Metabolic Disease Decades Early
Fasting blood glucose becomes abnormal when beta cell function has already declined by 50 percent or more. By that point, insulin resistance has typically been present for 10 to 20 years. Fasting insulin and HOMA-IR identify the metabolic dysfunction that precedes every manifestation of metabolic disease - often decades before any standard marker goes out of range.
- Insulin resistance is the root cause of type 2 diabetes, metabolic syndrome, and a primary driver of cardiovascular disease, certain cancers, and Alzheimer's disease. Fasting insulin is the most sensitive available biomarker for detecting insulin resistance before any other standard marker becomes abnormal.
- HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated from fasting insulin and fasting glucose and provides a composite measure of insulin resistance. HOMA-IR above 2.0 indicates significant insulin resistance; the longevity-optimal target is below 1.0.
- The standard reference range for fasting insulin (typically listed as below 25 uIU/mL) is wildly permissive - it reflects the average of a largely insulin-resistant population. The optimal longevity fasting insulin target is below 5 to 7 uIU/mL.
- A fasting insulin that is elevated but with a normal fasting glucose is the classic picture of compensated insulin resistance - the pancreas is working overtime to maintain normal glucose. This is the critical window for intervention before beta cell exhaustion leads to overt diabetes.
- The most effective interventions for lowering fasting insulin are: reducing refined carbohydrate and sugar intake, increasing aerobic exercise (particularly Zone 2 training), time-restricted eating, achieving and maintaining a healthy body weight, and improving sleep quality.
The global type 2 diabetes epidemic has a silent prelude that lasts decades. Insulin resistance - the reduced ability of cells to respond to insulin's signal to take up glucose - typically develops in the third or fourth decade of life in people who will eventually progress to type 2 diabetes. It is driven by the accumulation of ectopic lipid in insulin-sensitive tissues (liver, muscle, and pancreatic beta cells), chronic low-grade inflammation, visceral adiposity, and physical inactivity. For most of this time, fasting glucose and HbA1c appear completely normal, because the pancreas compensates by secreting ever-increasing amounts of insulin.1
The consequence of measuring only glucose: by the time fasting glucose exceeds the diagnostic threshold for prediabetes (100 mg/dL), beta cell function has already declined by an estimated 50 percent. The disease has been present and progressing for a decade or more. Measuring fasting insulin instead catches the dysfunction at the compensatory stage - when the pancreas is still producing enough insulin to maintain normal glucose but working far harder than it should be.
What Fasting Insulin Tells You
In a metabolically healthy, insulin-sensitive individual, the pancreas secretes relatively small amounts of insulin to maintain normal glucose disposal - fasting insulin typically runs between 2 and 6 uIU/mL in genuinely insulin-sensitive people. As insulin resistance develops, the pancreas must secrete progressively more insulin to achieve the same glucose disposal effect. Fasting insulin rises while fasting glucose remains normal - the defining characteristic of compensated insulin resistance.2
The standard lab reference range for fasting insulin (commonly listed as below 20 to 25 uIU/mL) was established from population norms rather than from optimal metabolic health outcomes. In a population where metabolic syndrome affects 35 percent of adults, population-normal is not the same as optimal. The longevity-relevant fasting insulin target is below 5 to 7 uIU/mL - a threshold consistent with the insulin levels seen in genuinely insulin-sensitive individuals and associated with the lowest cardiovascular and metabolic disease risk in longitudinal cohort data.
HOMA-IR: The Composite Measure
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) was developed by Matthews et al. in 1985 as a mathematical model estimating insulin resistance from fasting insulin and fasting glucose. The formula is: HOMA-IR = (fasting insulin in uIU/mL x fasting glucose in mg/dL) divided by 405. It combines information from both measures, accounting for the fact that glucose and insulin are jointly regulated and that their relationship reflects the degree of insulin resistance more accurately than either alone.3
"By the time someone's fasting glucose crosses into prediabetes territory, the train has been leaving the station for 10 to 15 years. Fasting insulin is the earliest warning signal we have."
Dr. Gerald Reaven, Stanford University, pioneer of insulin resistance researchInterpreting Your Numbers
| Fasting Insulin | HOMA-IR | Metabolic Status | Clinical Implication |
|---|---|---|---|
| <5 uIU/mL | <1.0 | Optimal insulin sensitivity | Longevity target range |
| 5-7 uIU/mL | 1.0-1.5 | Good insulin sensitivity | Acceptable, monitor trend |
| 7-10 uIU/mL | 1.5-2.0 | Early insulin resistance | Intervene with lifestyle now |
| 10-20 uIU/mL | 2.0-5.0 | Moderate insulin resistance | Aggressive lifestyle + consider CGM |
| >20 uIU/mL | >5.0 | Severe insulin resistance | Medical evaluation required |
Why Insulin Resistance Matters Beyond Diabetes
Insulin resistance is not merely a precursor to diabetes - it is a systemic metabolic disorder with consequences across every major organ system. Cardiovascular disease: insulin resistance drives the atherogenic dyslipidemia (high triglycerides, low HDL, small dense LDL, elevated ApoB), hypertension, and endothelial dysfunction that constitute the metabolic cardiovascular risk cluster. Cancer: insulin and IGF-1 are mitogenic - they promote cell proliferation and inhibit apoptosis. Chronically elevated insulin creates a hormonal environment that promotes tumor growth and is associated with elevated risk of colorectal, breast, endometrial, and pancreatic cancers. Alzheimer's disease: the brain is an insulin-sensitive organ, and insulin signaling is essential for synaptic plasticity, neuronal survival, and amyloid clearance. The term type 3 diabetes has been proposed for cases of Alzheimer's disease driven by brain insulin resistance.4
How to Lower Fasting Insulin
Reduce refined carbohydrate and added sugar intake - the primary dietary drivers of postprandial insulin hypersecretion and progressive beta cell exhaustion. Replacing ultra-processed carbohydrates with whole foods, protein, and fat reliably reduces fasting insulin in insulin-resistant individuals within weeks.5 Zone 2 aerobic exercise is the most potent non-dietary intervention - it directly increases GLUT4 transporter density in muscle cells, improving insulin-independent glucose disposal and significantly reducing the insulin required for glucose homeostasis. Four to five hours per week of Zone 2 exercise can produce dramatic reductions in HOMA-IR within 8 to 12 weeks. Time-restricted eating reduces insulin exposure by concentrating the eating window and extending the overnight fasting period during which insulin is at its lowest. Sleep optimization is underappreciated: even one night of partial sleep deprivation (4 hours) produces insulin resistance equivalent to 6 months of a high-fat diet in controlled studies.
References
- 1Tabak AG, et al. "Prediabetes: a high-risk state for diabetes development." Lancet. 2012;379(9833):2279-2290. [PubMed]
- 2Reaven GM. "Banting Lecture 1988: Role of insulin resistance in human disease." Diabetes. 1988;37(12):1595-1607. [PubMed]
- 3Matthews DR, et al. "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." Diabetologia. 1985;28(7):412-419. [PubMed]
- 4De Felice FG, Ferreira ST. "Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease." Diabetes. 2014;63(7):2262-2272. [PubMed]
- 5Volek JS, Phinney SD. "The Art and Science of Low Carbohydrate Living." Beyond Obesity LLC. 2011. [PubMed]